Director Yang Huang notified the company on October 4, 2026, that he will not seek re-election to the board of directors at the upcoming Annual and Special General Meeting of Shareholders scheduled for November 2, 2026. The filing also includes an amended proxy statement seeking shareholder approval for equity-based compensation grants: approximately $1.3 million in Restricted Share Units (RSUs) to CEO Eyal Shamir and a two-tranche grant totaling up to approximately $513,000 plus additional RSUs contingent on financing to Chairman Ron Mayron. The company operates in the medical device industry, developing cryoablation systems for oncology.
